From our cohort of 1,018 patients with indications of MDS, TET2, SF3B1, and ASXL1 were the most frequently mutated genes (in >10% of patients), followed by SRSF2, TP53, DNMT3A, and RUNX1 (in >5% of patients), similar to Haferlach and colleague’s study on the mutational profiles of 944 patients with MDS [36]. This evidence concerns the gene RUNX1 and myelodysplastic syndrome.